In recent years, ensartinib has become a new first-line treatment option for patients with ALK-positive NSCLC, which shows potent inhibition of wild-type ALK and most common crizotinib-resistant mutations (such as F1174 and C1156Y, G1269A, L1196M, S1206R, and T1151) [3]. This evidence concerns the gene ALK and non-small cell lung carcinoma.